|Bid||7.83 x 1100|
|Ask||7.84 x 1300|
|Day's Range||7.35 - 8.45|
|52 Week Range||1.08 - 24.90|
|Beta (5Y Monthly)||0.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Nov 09, 2012|
|1y Target Est||17.67|
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will host a conference call and provide a business update at 4:30 PM ET on Tuesday, March 2, 2021. Conference Call Dial-In & Webcast Information:Date: Tuesday, March 2, 2021Time:4:30 PM Eastern TimeDomestic:877-407-0784International:201-689-8560Conference ID:13716984Webcast:http://public.viavid.com/index.php?id=143739 About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Contacts Brant BiehnVaxart, Inc.650 550 3500IR@vaxart.comJoyce AllaireLifeSci Advisors, LLC617 435 email@example.com
Imagine a vaccine without the jab: That's Vaxart's specialty. The clinical-stage biotech company is developing oral vaccines for a variety of viruses -- including SARS-CoV-2, the virus that causes COVID-19. The company's shares soared more than 1,500% last year as Vaxart's investigational coronavirus vaccine made it through preclinical studies and began a human trial.
These are the small cap stocks with the best value, fastest growth, and most momentum for February 2021.